SG11201804673WA - Novel anti-claudin antibodies and methods of use - Google Patents
Novel anti-claudin antibodies and methods of useInfo
- Publication number
- SG11201804673WA SG11201804673WA SG11201804673WA SG11201804673WA SG11201804673WA SG 11201804673W A SG11201804673W A SG 11201804673WA SG 11201804673W A SG11201804673W A SG 11201804673WA SG 11201804673W A SG11201804673W A SG 11201804673WA SG 11201804673W A SG11201804673W A SG 11201804673WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cldn9
- cldn6
- rule
- california
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
International Patent Classification: A.; 3000 Monterey Street, San Mateo, California 94403 C07K 16/30 (2006.01) A61K 45/06 (2006.01) (US). CO7D 519/00 (2006.01) A61K 47/48 (2006.01) A61K 31/55 (2006.01) A61P 35/02 (2006.01) (74) Agents: MEIGS, Julie Broadus et al.; Womble Carlyle Sandridge & Rice, LLP, P.O. Box 7037, Atlanta, Georgia (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111M 11111111111111111111111111111111111111111111111111111111111111R111111111111111 (10) International Publication Number WO 2017/096163 Al WIPO I PCT (43) International Publication Date 8 June 2017 (08.06.2017) 30357 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/US2016/064617 (22) International Filing Date: 2 December 2016 (02.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/263,542 4 December 2015 (04.12.2015) US 62/427,027 28 November 2016 (28.11.2016) US (71) Applicant: ABBVIE STEMCENTRX LLC [US/US]; 1 North Waukegan Road, North Chicago, Illinois 60064 (US). (72) Inventors: FONG, Sarah; 4432 39th Avenue, Oakland, California 94619 (US). SISODIYA, Viltram Natwarsin- hji; 3615 22nd Street, Apt 23, San Francisco, California 94114 (US). STULL, Robert A.; 1519 Fifth Street, Alameda, California 94501 (US). WILLIAMS, Samuel (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, [Continued on next page] (54) Title: NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE Alignment of human CLDN6 and CLDN9 protein sequences (57) : Provided herein are nov- el anti-CLDN antibodies and antibody drug conjugates (ADC), including deriv- atives thereof, and methods of using the same to treat proliferative disorders. 1 60 CLDN6 masagmq ILGVVLTLLGWVNGLVSCALPMWEVTAFIGNSIVVAQVVWEGLWMSCVVQSTG III 1 H 1 III 1111111 1111111111111111111111111111111 CLDN9 mastgle LLGMTLAVLGWLGTLVSCALP LWKVTAFIGNSIVVAQVVWEGLWMSCVVQSTG 61 120 CLDN6 QMQCKVYDSLLALPQDLQAAF LOVIALLVALEGLLVYLAGAkcttcveekdskar VLT 111111111111111111111 11111111 II 1111 11 111111 111 III CLDN9 QMQCKVYDSLLALPQDLQAAF LCVIALLLALLGLLVAITGAgcttcvedegakarIVLT 121 180 CLDN6 SGIVFVISGVLTLIPV WTAHAI IRDFYNPLVAEAQKREI GASLYLGWAASGLLLLGGGL 1 1 1 1111 1111111 1111111111 1111 1111111111 11 11111 CLDN9 AGVILLLAGILVLIPV WTAHAI IQDFYNPLVAEALKREI GASLYLGWAAAALLMLCGGL 181 220 CLDN6 lcctcpsggsqgpshymarystsapaisrgpseyptknyv (SEQ ID NO: 10) 111111 I I I I I II 11 CLDN9 lcctcpppgverprg--prlgys±psrs-gasgldkrdyv (SEQ ID NO: 11) W O 20 17 /096 163 Al 217 FIG. 1B WO 2017/096163 Al MIDEDIt01111101011110E11 0ME11111111111111111111111111111111111111 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Published: GW, KM, ML, MR, NE, SN, TD, TG). with international search report (Art 21(3)) Declarations under Rule 4.17: before the expiration of the time limit for amending the as to applicant's entitlement to apply for and be granted claims and to be republished in the event of receipt of a patent (Rule 4. 17(ii)) amendments (Rule 48.2(h)) as to the applicant's entitlement to claim the priority of — with sequence listing part of description (Rule 5.2(a)) the earlier application (Rule 4.17(iii))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263542P | 2015-12-04 | 2015-12-04 | |
| US201662427027P | 2016-11-28 | 2016-11-28 | |
| PCT/US2016/064617 WO2017096163A1 (en) | 2015-12-04 | 2016-12-02 | Novel anti-claudin antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804673WA true SG11201804673WA (en) | 2018-06-28 |
Family
ID=58797837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804673WA SG11201804673WA (en) | 2015-12-04 | 2016-12-02 | Novel anti-claudin antibodies and methods of use |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20190083645A1 (en) |
| EP (1) | EP3383917A4 (en) |
| JP (1) | JP2019500335A (en) |
| KR (1) | KR20180088445A (en) |
| CN (1) | CN108473588A (en) |
| AU (1) | AU2016364853A1 (en) |
| BR (1) | BR112018011319A2 (en) |
| CA (1) | CA3006738A1 (en) |
| CL (2) | CL2018001481A1 (en) |
| CO (1) | CO2018005752A2 (en) |
| CR (1) | CR20180348A (en) |
| DO (1) | DOP2018000138A (en) |
| EC (1) | ECSP18049762A (en) |
| HK (1) | HK1254743A1 (en) |
| IL (1) | IL259681A (en) |
| MA (1) | MA43385A (en) |
| MX (1) | MX2018006782A (en) |
| PE (1) | PE20181302A1 (en) |
| PH (1) | PH12018501153A1 (en) |
| RU (1) | RU2018124319A (en) |
| SG (1) | SG11201804673WA (en) |
| TW (1) | TW201726175A (en) |
| WO (1) | WO2017096163A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40921A (en) * | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | ANTI-GENETIC CHEMERICAL ANTI-CLDN RECEPTORS AND METHODS OF USE |
| WO2018006882A1 (en) | 2016-07-08 | 2018-01-11 | 科济生物医药（上海）有限公司 | Antibody for anti-claudin 18a2 and use thereof |
| MY194477A (en) * | 2017-08-18 | 2022-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| CN111278462A (en) * | 2017-09-02 | 2020-06-12 | 艾伯维公司 | anti-EGFR Antibody Drug Conjugates (ADCs) and uses thereof |
| EP3675907A4 (en) * | 2017-09-02 | 2021-05-12 | AbbVie Inc. | Anti-egfr antibody drug conjugates (adc) and uses thereof |
| IL301638A (en) | 2017-09-29 | 2023-05-01 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| US20210283141A1 (en) * | 2018-05-25 | 2021-09-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| MA54955A (en) * | 2019-02-15 | 2021-12-22 | Integral Molecular Inc | ANTI-CLAUDINE 6 ANTIBODIES AND THEIR USES |
| WO2020191342A1 (en) * | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
| TW202102228A (en) | 2019-03-25 | 2021-01-16 | 日商第一三共股份有限公司 | Antibody-pyrrolobenzodiazepine derivative conjugate |
| WO2021088927A1 (en) | 2019-11-05 | 2021-05-14 | Lanova Medicines Limited Company | Antibody-drug conjugates targeting claudin 18.2 |
| AR124681A1 (en) | 2021-01-20 | 2023-04-26 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
| KR102451185B1 (en) * | 2021-08-05 | 2022-10-07 | 환인제약 주식회사 | A sustained-release microsphere comprising donepezil |
| CN114878728A (en) * | 2022-05-06 | 2022-08-09 | 浙江大学 | Novel antibody peptide pattern detection reduction method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2425309B (en) * | 2003-12-31 | 2008-07-09 | Council Scient Ind Res | C2-fluoro pyrrolo[2,1-c][1,4]benzodiazepine dimers |
| US7189710B2 (en) * | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| AU2011239522B2 (en) * | 2010-04-15 | 2014-10-23 | Medimmune Limited | Targeted pyrrolobenzodiazapine conjugates |
| RS58921B1 (en) * | 2012-10-12 | 2019-08-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| US10053511B2 (en) * | 2013-11-06 | 2018-08-21 | Abbvie Stemcentrx Llc | Anti-claudin antibodies and methods of use |
-
2016
- 2016-12-02 CA CA3006738A patent/CA3006738A1/en not_active Abandoned
- 2016-12-02 MX MX2018006782A patent/MX2018006782A/en unknown
- 2016-12-02 US US15/781,110 patent/US20190083645A1/en not_active Abandoned
- 2016-12-02 AU AU2016364853A patent/AU2016364853A1/en not_active Abandoned
- 2016-12-02 EP EP16871574.6A patent/EP3383917A4/en not_active Withdrawn
- 2016-12-02 RU RU2018124319A patent/RU2018124319A/en not_active Application Discontinuation
- 2016-12-02 BR BR112018011319A patent/BR112018011319A2/en not_active Application Discontinuation
- 2016-12-02 TW TW105140027A patent/TW201726175A/en unknown
- 2016-12-02 KR KR1020187018615A patent/KR20180088445A/en unknown
- 2016-12-02 PE PE2018001064A patent/PE20181302A1/en unknown
- 2016-12-02 CR CR20180348A patent/CR20180348A/en unknown
- 2016-12-02 JP JP2018528056A patent/JP2019500335A/en active Pending
- 2016-12-02 MA MA043385A patent/MA43385A/en unknown
- 2016-12-02 SG SG11201804673WA patent/SG11201804673WA/en unknown
- 2016-12-02 CN CN201680077475.8A patent/CN108473588A/en active Pending
- 2016-12-02 WO PCT/US2016/064617 patent/WO2017096163A1/en active Application Filing
-
2018
- 2018-05-29 IL IL259681A patent/IL259681A/en unknown
- 2018-05-31 PH PH12018501153A patent/PH12018501153A1/en unknown
- 2018-05-31 CO CONC2018/0005752A patent/CO2018005752A2/en unknown
- 2018-06-01 CL CL2018001481A patent/CL2018001481A1/en unknown
- 2018-06-01 DO DO2018000138A patent/DOP2018000138A/en unknown
- 2018-07-03 EC ECSENADI201849762A patent/ECSP18049762A/en unknown
- 2018-10-27 HK HK18113756.7A patent/HK1254743A1/en unknown
-
2019
- 2019-01-24 CL CL2019000189A patent/CL2019000189A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12018501153A1 (en) | 2019-01-28 |
| AU2016364853A1 (en) | 2018-06-21 |
| ECSP18049762A (en) | 2018-07-31 |
| CA3006738A1 (en) | 2017-06-08 |
| MX2018006782A (en) | 2018-11-09 |
| KR20180088445A (en) | 2018-08-03 |
| CL2018001481A1 (en) | 2018-08-24 |
| EP3383917A4 (en) | 2019-08-21 |
| PE20181302A1 (en) | 2018-08-09 |
| WO2017096163A1 (en) | 2017-06-08 |
| HK1254743A1 (en) | 2019-07-26 |
| MA43385A (en) | 2018-10-10 |
| BR112018011319A2 (en) | 2018-12-04 |
| IL259681A (en) | 2018-07-31 |
| RU2018124319A (en) | 2020-01-09 |
| EP3383917A1 (en) | 2018-10-10 |
| CO2018005752A2 (en) | 2018-06-12 |
| US20190083645A1 (en) | 2019-03-21 |
| CR20180348A (en) | 2018-08-23 |
| TW201726175A (en) | 2017-08-01 |
| CL2019000189A1 (en) | 2019-06-07 |
| DOP2018000138A (en) | 2018-12-31 |
| JP2019500335A (en) | 2019-01-10 |
| CN108473588A (en) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201805784PA (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| SG11201901597UA (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof |